Doctor-led aesthetics in Sutton Coldfield
MDr MaryamAesthetics

Polynucleotides

Polynucleotide injection depth: what does the 2026 split-face study show?

A 2026 study found broadly comparable short-term skin measurements with intradermal and subdermal polynucleotide delivery, but injection depth is not a simple choice between visible bumps and no downtime.

5 minute read

What does injection depth mean?

Intradermal treatment places small deposits within the skin, often using multiple needle points. This commonly creates temporary raised points or papules. Subdermal treatment places the product just beneath the dermis and may use a cannula to distribute it over a wider area. These are different procedures, even when the product and total volume are the same.

Depth affects where the material sits, how it spreads and which structures the practitioner must avoid. It may also change discomfort and early appearance. However, technique should not be selected from a social-media video or because one option sounds newer. The treatment area, skin thickness, concern, anatomy, product instructions and the practitioner’s competence all matter.

How was the 2026 study designed?

The prospective study enrolled 40 adults seeking improvement in facial wrinkles. Everyone received three sessions at three-week intervals: intradermal injections to the left infraorbital cheek and subdermal delivery to the right. Ultrasound was used to confirm the intended plane. Thirty-seven participants contributed follow-up imaging data at weeks nine and twelve.

The main outcome was change in a three-dimensional imaging measure of fine lines. Other measurements included wrinkles, roughness, pores, tone-related indices and elasticity. Participants and investigators also rated aesthetic improvement, while the researchers recorded pain, visible injection-site embossing and adverse events. This was a structured technique study, not a comparison with no treatment.

What did the study find?

Both sides showed short-term improvement from baseline in fine-line and several skin-quality measurements. Subdermal delivery met the study’s prespecified statistical definition of non-inferiority for fine-line improvement at weeks nine and twelve. Most between-side differences for other outcomes were small, and the authors described the overall responses as broadly comparable rather than proving one plane superior.

Pain scores were lower on the subdermal side after each session. Visible embossing occurred only after intradermal treatment in this study, whereas none was recorded on the subdermal side. That finding is useful when discussing immediate downtime, but it does not mean that subdermal treatment is painless, risk-free or free from swelling and bruising.

Why the result needs careful interpretation

The left side always received intradermal treatment and the right always received subdermal treatment; the side was not randomised. Natural asymmetry, sleeping side, sun exposure or operator handedness could therefore influence results. The non-inferiority margin was based partly on clinical judgement rather than a validated threshold for a visibly meaningful change.

Participants were young on average, most were women, and follow-up ended at twelve weeks. The study cannot tell us whether the techniques remain comparable long term, how repeated courses behave or whether its result applies to every facial area and PN formulation. Secondary analyses were exploratory, and the product manufacturer funded the study. Wider randomised evidence remains small and heterogeneous.

Downtime and adverse effects still matter

Either approach involves facial injections. Stinging, tenderness, redness, swelling, bruising, itching and pinpoint bleeding can occur. Intradermal deposits may remain visible as small raised points for a short period, while a cannula entry point and deeper passage can still cause soreness, swelling or bruising. Individual recovery cannot be guaranteed from an average study result.

Increasing pain, spreading redness or heat, discharge, fever, marked swelling, persistent lumps, unusual pale or mottled skin, eye pain or any visual change needs prompt clinical assessment. Small studies cannot reliably detect uncommon complications. Sterile technique, an authentic traceable product, written aftercare and access to timely review remain essential whichever plane is used.

Technique belongs within an individual consultation

Consultation should first define the concern—such as fine lines, texture, dryness or another diagnosis—and assess whether polynucleotides are likely to address it. Medical conditions, medicines, allergies and product ingredients, pregnancy or breastfeeding, active infection or inflammation, previous procedures and planned events should be reviewed before choosing a treatment or technique.

A responsible discussion covers the evidence limits, likely subtle change, number of sessions, downtime, alternatives, cost and follow-up. The GMC requires clear information about risks, lower-risk options and what happens if expectations are not met. The study supports another possible delivery approach under its specific protocol; it does not replace anatomical assessment or justify one standard technique for everyone.

← Back to the journal

Personalised medical assessment

Questions about treatment?

Book a consultation to discuss your concerns, health and treatment options without pressure.

Free consultation – a £1 booking fee secures your appointment